Table 2 Detailed clinical and prognostic data of patients treated with NSAİDs and steroids.
NSAİDs responders | No clinical response with NSAIDs | Recurrence in NSAIDs responders | Permenant hypothyroidism in NSAIDs responders | Steroid respnders* | Recurrence in steroid responders | Permenant hypothyroidism in steroid responders | |
|---|---|---|---|---|---|---|---|
n (female/male) | 51 (43/8) | 75 (62/13) | 7 (7/0) | 9 (8/1) | 91 (71/20) | 21 (18/3) | 6 (4/2) |
Age (year) | 42 ± 9 | 43 ± 10 | 42 ± 6 | 41 ± 7 | 43 ± 8 | 41 ± 6 | 46 ± 9,5 |
WBC (103/uL) | 8397 ± 1993 | 9227 ± 2719 | 7542 ± 1252 | 8387 ± 2187 | 10031 ± 2663 | 11242 ± 2855 | 10517 ± 4122 |
Neut (103/uL) | 5607 ± 1690 | 6406 ± 2489 | 4767 ± 1338 | 5476 ± 1604 | 6824 ± 2166 | 7940 ± 2725 | 6755 ± 2149 |
Treatment period (day) | 26 (14–42) | 9.5 (2–28) | 28 (14–42) | 21 (14–28) | 42 (14–70) | 42 (30–56) | 42 (14–42) |
ESR (mm/h) | 42,5 (8–105) | 51,5 (16–120) | 19 (13–99) | 43,5 (9–105) | 54 (9–120) | 54 (12–84) | 68 (18–81) |
CRP (mg/L) | 19 (2–191) | 54 (4–300) | 11 (5–101) | 48 (7–191) | 46 (3–202) | 42 (7–169) | 39 (3–162) |
TSH (mIU/L) | 0,06 (0,003–8,1) | 0,07 (0,003–7,1) | 0,7 (0,04–4,3) | 0,05 (0,01–8,1) | 0,03 (0,0001–3,4) | 0,14 (0,003–1,8) | 0,04 (0,001–0,3) |
fT4 (ng/dL) | 1,7 ± 0,8 | 1,9 ± 1 | 1,25 ± 0,75 | 1,62 ± 0,72 | 1,97 ± 1 | 1,58 ± 0,66 | 1,94 ± 0,83 |
fT3 (ng/L) | 4,4 (2,6–10,8) | 4,4 (2,7–11,8) | 5,2 (3,5–6,9) | 4,3 (3,4–10,8) | 4,7 (2,8–9,2) | 4,9 (2,8–6,3) | 3,7 (2,8–6,6) |
